Louise Hill presented the findings of a NeoVanc sub-study at ESPID’s 2020 Virtual Meeting in late October. Below is a summary of the study and findings.
Enterococcus (a bacterium) and candida (a fungus) can sometimes be found on or in the human body. Occasionally enterococci can develop resistance to one of the antibiotics usually used to treat it – vancomycin.
Vancomycin use has been linked to a rise in vancomycin-resistant enterococci and candida on or in the bodies of babies admitted to the neonatal intensive care unit.
We are pleased to celebrate the milestone achievement of the randomisation of 200 participants in the NeoVanc project. Congratulations to all the NeoVanc team!
A special mention needs to be made on the great effort of investigators, co-investigators and all researchers at recruiting sites involved in this key study on the use of Vancomycin in paediatrics. We look forward to continuing our work together towards reaching the project target of 300 evaluable participants and we wish the NeoVanc team the best of luck!